Tratamiento de cáncer de pulmón metastásico (estadio IV) de célula no pequeña : consenso de expertos, Asociación Colombiana de Hematología y Oncología (ACHO).

Treatment of non-small cell metastatic lung cancer (stage IV) : expert consensus, Colombian Association of Hematology and Oncology (ACHO).

Publicado 2018-07-01

Abrir | Descargar
PDF FLIP
Número
Vol. 5 Núm. 1 (2018): Julio
Sección
Artículo especial
Cómo citar
Tratamiento de cáncer de pulmón metastásico (estadio IV) de célula no pequeña : consenso de expertos, Asociación Colombiana de Hematología y Oncología (ACHO).
Rev. colomb. hematol. oncol. [Internet]. 2018 Jul. 1 [cited 2024 Dec. 22];5(1):61-7. Disponible en: https://doi.org/10.51643/22562915.364
DOI

https://doi.org/10.51643/22562915.364
Dimensions
PlumX
Licencia
Creative Commons License

Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.

Aylen Vanessa Ospina
Fundación Santa Fe de Bogotá
    Ricardo Brugés
    Hospital Universitario San Ignacio
      Mauricio Lema
      Clínica de Oncología Astorga
        Gilberto de Lima Lopes Jr.
        University of Miami
          Rodolfo Gómez
          IDC Las Américas
            Mostrar biografía de los autores

            Aylen Vanessa Ospina,

            Médica, oncóloga clínica. ICCAL Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá.

            Ricardo Brugés,

            Médico, oncólogo clínico. Instituto Nacional de Cancerología, Hospital Universitario San Ignacio, Bogotá

            Mauricio Lema,

            Médico, hematooncólogo. Clínica de Oncología Astorga, Medellín.

            Gilberto de Lima Lopes Jr.,

            Médico, MBA, FAMS. Director médico de programas internacionales y director asociado oncología global, Sylvester Comprehensive Cancer Center, University of Miami.

            Rodolfo Gómez,

            Médico, oncólogo clínico. IDC Las Américas, Medellín.

            Milton Lombana,

            Médico, hematooncólogo. Clínica de Occidente, Cali.

            Carlos Vargas,

            Médico, oncólogo clínico. Clínica El Country, Bogotá.

            Ricardo Duarte,

            Médico, oncólogo clínico. Clínica Reina Sofía - Colsanitas, Bogotá.

            José Lobatón,

            Médico, hematooncólogo. IMAT Oncomédica, Montería.

            Andrés Yepes,

            Médico, oncólogo clínico. Clínica Vida Fundación, Medellín

            Ray Manneh,

            Médico, oncólogo clínico. Sociedad de Hematología y Oncología del Cesar - Clínica Portoazul, Valledupar, Barranquilla.

            Luis Pino,

            Médico, hematooncólogo. Hospital Militar Central, Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá.

            Jaime González,

            Médico, hematooncólogo. Oncólogos de Occidente, Manizales, Armenia, Pereira

            Diego Gómez,

            Médico, oncólogo clínico. CAL Oncólogos, Bucaramanga.

            Jesús Insuasty,

            Médico, oncólogo clínico. Profesor del Departamento de Medicina Interna UIS, Hospital Universitario de Santander, Bucaramanga.

            Pedro Ramos,

            Médico, oncólogo clínico. Oncocare - Sanitas EPS, Bogotá.

            Javier Godoy,

            Médico, hematooncólogo. Clínica de Marly, Bogotá.

            Álvaro Gómez,

            Médico, hematooncólogo. Hemato Oncólogos - Instituto de Oncología, Cali.

            Carlos Alberto Castro,

            Médico, epidemiólogo. SIIES Consultores, Investigación y Educación en Salud, Fundación Universitaria de Ciencias de la Salud, Bogotá.

            Introducción: el cáncer de pulmón (CP) es la causa más frecuente de muertes por patologías oncológicas en el mundo1, reportando tasas de incidencia para ambos sexos de 23,1 casos por cada 100 mil habitantes y una mortalidad del 19,4%, según Globocan 20122. Objetivo: consensuar por común acuerdo de expertos recomendaciones para el manejo del cáncer de pulmón metastásico (estadio IV) de célula no pequeña en el contexto colombiano. Métodos: se estructuró un consenso de expertos constituido por 17 oncólogos clínicos, miembros activos de la Asociación Colombiana de Hematología y Oncología (ACHO), que laboran en las principales instituciones del país. Se llevó a cabo en cuatro fases: en la primera fase, se definieron 22 preguntas, las cuales fueron calificadas de 1 a 9; en la segunda, se reenviaron de nuevo las preguntas no consensuadas; en la tercera, se analizaron y discutieron las respuestas; y las no consensuadas fueron a una cuarta fase, donde se hizo un consenso nominal. Resultados: se evaluaron y discutieron 25 preguntas relacionadas con el tratamiento de cáncer de pulmón metastásico (estadio IV) de célula no pequeña y se concluyeron recomendaciones basadas en la mejor evidencia científica y en guías de manejo de oncología reconocidas internacionalmente adaptadas al contexto y realidad colombiana. Conclusiones: se deben considerar los tratamientos para el cáncer de pulmón avanzado según la mejor evidencia científica y la disponibilidad en Colombia, con el fin de ofrecer el mejor tratamiento al paciente. Este consenso es una herramienta para orientar la toma de decisiones clínicas y es útil como documento soporte para consultas de entes públicos y privados. Es importante mencionar que este es un texto académico-científico y no regulatorio.

            Visitas del artículo 634 | Visitas PDF 439

            1. Arrieta O, Guzmán-De Alba E, López LF, Acosta-Espinoza A, Latorre-Alexander J, Meza JF, et al. Consenso nacional de diagnóstico y tratamiento del cáncer de pulmón de células no pequeñas. Revista de Investigación Clínica. 2013;5(S1):5-84.
            2. Globocan. Lung cancer estimated incidence, mortality and prevalence worldwide in 2012. [internet]. Francia; 2012 [citado 2018]. Disponible en: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx
            3. Instituto Nacional de Cáncer. Cancer statistics review, 1975- 2002. EE. UU.; 2007 [citado 2018]. Disponible en: https://seer.cancer.gov/archive/csr/1975_2002/
            4. American Cancer Society. Cáncer de pulmón de células no pequeña: estadísticas, EE. UU. Cancer.net [internet]. 2017. [citado 2018]. Disponible en https://www.cancer.net/es/tipos-de-c%C3%A1ncer/c%C3%A1ncer-de-pulm%C3%B3nc%C3%A9lulas-no-peque%C3%B1as/estad%C3%ADsticas
            5. Ministerio de Salud y Protección Social de Colombia. Guía de práctica clínica para la detección temprana, diagnóstico, estadificación y tratamiento del cáncer de pulmón. Guía para profesionales de la salud. [internet]. Colombia; 2014. [citado 2018]. Disponible en http://gpc.minsalud.gov.co/gpc_sites/repositorio/forms/allitems.aspx?rootfolder=/gpc_sites/repositorio/conv_563/gpc_c_pulmon&folderctid=0x012000f43cfde8d8154047b4b4b9b88e72b8b7&view=%7Bc81f0233-558c-49afa456-55fa1462ce27%7D
            6. Instituto Nacional de Cancerología. Análisis de situación del cáncer en Colombia 2015 [internet]. [citado 2018]. Disponible en https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0ahUKEwiV96a48fXbAhWOv1MKHSb-IYQFggnMAA&url=http%3A%2F%2Fwww.cancer.gov.co%2FSituacion_del_Cancer_en_Colombia_2015.pdf&usg=AOvVaw17RZT_CxhHpz3dbWC_tzQ6
            7. Cuenta de Alto Costo-Fondo Colombiano de Enfermedades de Alto Costo. Indicadores de gestión del riesgo en pacientes con cáncer de pulmón. Colombia; 2018. [citado 2018]. Disponible en https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=21&ved=0ahUKEwibu-bIgO3aAhWC7FMKHSsDA9U4ChAWCFcwCg&url=https%3A%2F%2Fcuentadealtocosto.org%2Fsite%2Fimages%2FIndicadores_de_gestion_del_riesgo_en_pacientes_con_Cancer_de_Pulmon.pdf&usg=AOvVaw38adFfKnJX8glkn-GmDcnm
            8. Castro C, Cardona AF, Revéiz L, Serrano SJ, Carranza H, Vargas CA, et al. Cáncer de pulmón de célula no pequeña metastásico. Tratamiento actual basado en la evidencia (OncolGroup). Acta Médica Colombiana. 2010;35:53-81.
            9. Gettinger S. Immunotherapy of advanced non-small cell lung cancer with immune checkpoint inhibition. UpToDay [internet]. 2018. [citado 2018]. Disponible en: https://uptoday/contents/immunotherapy-of-advanced-non-small-cell-lung-cancer-withimmune-checkpoint-inhibition?search=inmunotherapylungcancer&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1
            10. National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Non-small cell lung cancer. [internet]. EE. UU.; 2018. [citado 2018]. Disponible en: https://www.nccn.org/professionals/physician_gls/default.aspx#nscl
            11. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung can cer (keynote-010): a randomised controlled trial. Lancet. 2016;387(10027):1540-50.
            12. Barlesi F, Mazieres J, Merlio JP, Debieuvre D, Mosser J, Lena H, et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet. 2016;387(10026):1415-26.
            13. Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311(19):1998-2006.
            14. Leighl NB, Rekhtman N, Biermann WA, Huang J, Mino-Kenudson M, Ramalingam SS, et al. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline. J Clin Oncol. 2014;32(32):3673-9.
            15. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med. 2013;137(6):828-60.
            16. Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012;30(8):863-70.
            17. Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med. 2018;142(3):321-46.
            18. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol. 2013;8(7):823-59.
            19. Sacher AG, Paweletz C, Dahlberg SE, Alden RS, O’Connell A, Feeney N, et al. Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer. JAMA Oncol. 2016;2(8):1014-22.
            20. Wu YL, Sequist LV, Hu CP, Feng J, Lu S, Huang Y, et al. EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6. Br J Cancer. 2017;116(2):175-85.
            21. Gridelli C, Ciardiello F, Gallo C, Feld R, Butts C, Gebbia V, et al. First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. J Clin Oncol. 2012;30(24):3002-11.
            22. Brugger W, Triller N, Blasinska-Morawiec M, Curescu S, Sakalauskas R, Manikhas GM, et al. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol. 2011;29(31):4113-20.
            23. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, Juhasz E, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomized, placebo-controlled phase 3 study. Lancet Oncol. 2010;11(6):521-9.
            24. Rosell R, Dafni U, Felip E, Curioni-Fontecedro A, Gautschi O, Peters S, et al. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. Lancet Respir Med. 2017;5(5):435-44.
            25. Seto T, Kato T, Nishio M, Goto K, Atagi S, Hosomi Y, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 2014;15(11):1236-44.
            26. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2005;23(25):5892-9.
            27. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial- -INTACT 1. J Clin Oncol. 2004;22(5):777-84.
            28. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. J Clin Oncol. 2004;22(5):785-94.
            29. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-smallcell lung cancer (OPTIMAL, CTONG-0802). Ann Oncol. 2015;26(9):1877-83.
            30. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as firstline treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomized phase 3 trial. Lancet Oncol. 2012;13(3):239-46.
            31. Wu YL, Zhou C, Liam CK, Wu G, Liu X, Zhong Z, et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol. 2015;26(9):1883-9.
            32. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947-57.
            33. Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, firstline study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011;29(21):2866-74.
            34. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11(2):121-8.
            35. Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol. 2013;24(1):54-9.
            36. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for nonsmall-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380-8.
            37. Oizumi S, Kobayashi K, Inoue A, Maemondo M, Sugawara S, Yoshizawa H, et al. Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial. Oncologist. 2012;17(6):863-70.
            38. Miller VA, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 2012;13(5):528-38.
            39. Wu YL, Zhou C, Hu C-P, Feng JF, Lu S, Huang Y, et al. LUXLung 6: a randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung. J Clin Oncol. 2013;31(15 suppl):8016.
            40. Sequist LV, Yang JC, Yamamoto N, O’Byrne K, Hirsh V, Mok T, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3327-34.
            41. Yang JC, Hirsh V, Schuler M, Yamamoto N, O’Byrne KJ, Mok TS, et al. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3342-50.
            42. Katakami N, Atagi S, Goto K, Hida T, Horai T, Inoue A, et al. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol. 2013;31(27):3335-41.
            43. Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomized phase 3 trial. Lancet Oncol. 2014;15(2):213-22.
            44. Food and Drug Administration. Approved drug products, 2018. [internet]. EE. UU.; 2018. [citado 2018]. Disponible en https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=reportsSearch.process]
            45. Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, et al. Alectinib versus crizotinib in patients with ALK-positive nonsmall-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet. 2017;390(10089):29-39.
            46. Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, et al. Alectinib versus crizotinib in untreated ALK-positive nonsmall-cell lung cancer. N Engl J Med. 2017;377(9):829-38.
            47. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167-77.
            48. Soria JC, Tan DSW, Chiari R, Wu YL, Paz-Ares L, Wolf J, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomized, open-label, phase 3 study. Lancet. 2017;389(10072):917-29.
            49. Ou SH, Jänne PA, Bartlett CH, Tang Y, Kim DW, Otterson GA, et al. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Ann Oncol. 2014;25(2):415-22.
            50. Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFRmutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113-25.
            51. Nishie K, Kawaguchi T, Tamiya A, Mimori T, Takeuchi N, Matsuda Y, et al. Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: a retrospective analysis for Japanese patients with activating EGFR mutations. J Thorac Oncol. 2012;7(11):1722-7.
            52. Jänne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372(18):1689-99.
            53. Soria JC, Wu YL, Nakagawa K, Kim SW, Yang JJ, Ahn MJ, et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomized trial. Lancet Oncol. 2015;16(8):990-8.
            54. Yang JC, Ahn MJ, Kim DW, Ramalingam SS, Sequist LV, Su WC, et al. Osimertinib in pretreated T790M-positive advanced nonsmall-cell lung cancer: AURA study phase II extension component. J Clin Oncol. 2017;35(12):1288-96.
            55. Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomized trial. Lancet. 2004;363(9422):1665-72.
            56. Kondziolka D, Patel A, Lunsford LD, Kassam A, Flickinger JC. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys. 1999;45(2):427-34.
            57. Zhou L, He J, Xiong W, Liu Y, Xiang J, Yu Q, et al. Impact of whole brain radiation therapy on CSF penetration ability of icotinib in EGFR-mutated non-small cell lung cancer patients with brain metastases: results of phase I dose-escalation study. Lung Cancer. 2016;96:93-100.
            58. Zeng YD, Liao H, Qin T, Zhang L, Wei WD, Liang JZ, et al. Blood-brain barrier permeability of gefitinib in patients with brain metastases from non-small-cell lung cancer before and during whole brain radiation therapy. Oncotarget. 2015;6(10):8366-76.
            59. Deng Y, Feng W, Wu J, Chen Z, Tang Y, Zhang H, et al. The concentration of erlotinib in the cerebrospinal fluid of patients with brain metastasis from non-small-cell lung cancer. Mol Clin Oncol. 2014;2(1):116-20.
            60. Togashi Y, Masago K, Fukudo M, Terada T, Fujita S, Irisa K, et al. Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer. J Thorac Oncol. 2010;5(7):950-5.
            61. Tamiya A, Tamiya M, Nishihara T, Shiroyama T, Nakao K, Tsuji T, et al. 1241P - Afatinib efficacy and cerebrospinal fluid concentration in NSCLC patients with EGFR mutation developing leptomeningeal carcinomatosis. ESMO 2016 Congress. [internet]. 2016 [citado 2018]. Disponible en: http://oncologypro.esmo.org/Meeting-Resources/ESMO-2016/Afatinib-efficacy-and-cerebrospinal-fluid-concentration-in-NSCLC-patients-with-EGFRmutation-developing-leptomeningeal-carcinomatosis
            62. Ballard P, Yates JW, Yang Z, Kim DW, Yang JC, Cantarini M, et al. Preclinical comparison of osimertinib with other EGFRTKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res. 2016;22(20):5130-40.
            63. Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFRmutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113-25.
            64. Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371(21):1963-71.
            65. Wu YL, Yang JC, Kim DW, Lu S, Zhou J, Seto T, et al. Phase II study of crizotinib in East Asian patients with ROS1- positive advanced non-small-cell lung cancer. J Clin Oncol. 2018;36(14):1405-11.
            66. Lim SM, Kim HR, Lee JS, Lee KH, Lee YG, Min YJ, et al. Openlabel, multicenter, phase II study of ceritinib in patients with non-small-cell lung cancer harboring ROS1 rearrangement. J Clin Oncol. 2017;35(23):2613-8.
            67. Drilon A, Somwar R, Wagner JP, Vellore NA, Eide CA, Zabriskie MS, et al. A novel crizotinib-resistant solvent-front mutation responsive to cabozantinib therapy in a patient with ROS1- rearranged lung cancer. Clin Cancer Res. 2016;22(10):2351-8.
            68. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018-28.
            69. Barlesi F, Scherpereel A, Rittmeyer A, Pazzola A, Ferrer Tur N, Kim JH, et al. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol. 2013;31(24):3004-11.
            70. Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland A, et al. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-smallcell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017;18(10):1307-16.
            71. Planchard D, Besse B, Groen HJM, Souquet PJ, Quoix E, Baik CS, et al. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 2016;17(7):984-93.
            72. Delbaldo C, Michiels S, Syz N, Soria JC, Le Chevalier T, Pignon JP. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA. 2004;292(4):470-84.
            73. Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M, et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2007;99(11):847-57.
            74. Fidias PM, Dakhil SR, Lyss AP, Loesch DM, Waterhouse DM, Bromund JL, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 2009;27(4):591-8.
            75. Pérol M, Chouaid C, Pérol D, Barlési F, Gervais R, Westeel V, et al. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2012;30(28):3516-24.
            76. Rodríguez PC, Neninger E, García B, Popa X, Viada C, Luaces P, et al. Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an epidermal growth factor (EGF) based cancer vaccine in advanced non-small cell lung cancer (NSCLC) patients. J Immune Based Ther Vaccines. 2011;9:7.
            77. Rodríguez PC, Popa X, Martínez O, Mendoza S, Santiesteban E, Crespo T, et al. A phase III clinical trial of the epidermal growth factor vaccine CIMAvax-EGF as switch maintenance therapy in advanced non-small cell lung cancer patients. Clin Cancer Res. 2016;22(15):3782-90.
            78. Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, et al. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: twoyear outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017;35(35):3924-33.
            79. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123-35.
            80. Peters S, Gettinger S, Johnson ML, Jänne PA, Garassino MC, Christoph D, et al. Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed deathligand 1-selected advanced non-small-cell lung cancer (BIRCH). J Clin Oncol. 2017;35(24):2781-9.
            81. American Cancer Society. Medicamentos de terapia dirigida para el cáncer de pulmón no microcítico. [internet]. EE. UU.; 2017 [citado 2018]. Disponible en: https://www.cancer.org/es/cancer/cancer-de-pulmon-no-microcitico/tratamiento/terapiasdirigidas.html
            82. National Center for Biotechnology Information. ROS1 ROS proto-oncogene 1, receptor tyrosine kinase [Homo sapiens (human)]. [internet]. EE. UU.; 2018 [citado 2018]. Disponible en: https://www.ncbi.nlm.nih.gov/gene/6098
            83. National Center for Biotechnology Information. Programmed cell death 1 ligand 1. [internet]. EE. UU.; 2017 [citado 2018]. Disponible en: https://www.ncbi.nlm.nih.gov/gene/100196322
            84. Genetics Home Reference - National Library of Medicine. B-RAF proto-oncogene, serine/threonine kinase. [internet]. EE. UU.; 2017 [citado 2018]. Disponible en: https://ghr.nlm.nih.gov/gene/BRAF
            85. Eastern Cooperative Oncology Group. ECOG performance status. [internet]. EE. UU.; 2018 [citado 2018]. Disponible en: http://ecog-acrin.org/resources/ecog-performance-status

            Información

            Directorios e indexadores
            Perfil de Google Scholar

            Código QR

            Palabras clave

            Más leídos en los últimos 30 días

            Número actual

            Sistema OJS 3.4.0.7 - Metabiblioteca |